Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Meniru, G. I
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meniru, G. I
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 6, 1409-1411, June 1999
© 1999 European Society of Human Reproduction and Embryology

Debate

Is Puregon a `good' or `super' drug?

Godwin I Meniru1

Departments of Reproductive Medicine, Obstetrics and Gynaecology, Jerudong Park Medical Centre, Jerudong Park BG 3122, Brunei Darussalam

There is still a paucity of published real-life clinical experience with the use of first generation recombinant follicle stimulating hormone (rFSH) preparations. Ebullient reports, a major proportion of which originated from industry-sponsored or -associated research, have unanimously proclaimed the efficacy of both rFSH preparations that have come onto the market recently (Follitropin ß; Puregon; NV Organon, Oss, The Netherlands; and Follitropin {alpha}; Gonal F; Ares-Serono, Geneva, Switzerland). The same group of reports, incidentally, have stressed the shortcomings of previously utilized, urinary-derived gonadotrophin preparations (uroG) in a manner which the industry never used prior to the recent marketing blitz of rFSH. It is not clear why one company (NV Organon, Oss, The Netherlands) tested its rFSH, Puregon, against an older generation and named uroG (Metrodin) of the competitor (Ares-Serono, Geneva, Switzerland) rather than use its own (named) products. No `conflict of interest' declarations by industry employed or associated authors were in . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
H. Al-Inany, M. Aboulghar, R. Mansour, and G. Serour
Meta-analysis of recombinant versus urinary-derived FSH: an update
Hum. Reprod., February 1, 2003; 18(2): 305 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens
From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study
Hum. Reprod., April 1, 2002; 17(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. Sykes, H. J. Out, S. J. Palmer, and J. v. Loon
The cost-effectiveness of IVF in the UK: a comparison of three gonadotrophin treatments
Hum. Reprod., December 1, 2001; 16(12): 2557 - 2562.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. J. Out, I. David, R. Ron-El, S. Friedler, E. Shalev, J. Geslevich, J. Dor, A. Shulman, Z. Ben-Rafael, B. Fisch, et al.
A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles
Hum. Reprod., June 1, 2001; 16(6): 1104 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
H. J. Out, H. J.T.C. Bennink, and W. N.G.M. de Laat
What are the clinical benefits of recombinant gonadotrophins?: The development of recombinant FSH (Puregon(R)): a scientific business
Hum. Reprod., September 1, 1999; 14(9): 2189 - 2190.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
A. H. Balen, C. J. Hayden, and A. J. Rutherford
Clinical efficacy of recombinant gonadotrophins
Hum. Reprod., June 1, 1999; 14(6): 1411 - 1417.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
E.R. Hernandez
The good, the bad and the ugly
Hum. Reprod., June 1, 1999; 14(6): 1417 - 1418.
[Full Text] [PDF]